Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-12-15
2001-06-26
Ramsuer, Robert W. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S316000
Reexamination Certificate
active
06251914
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a novel group of imidazole compounds, processes for the preparation thereof, the use thereof in treating cytokine mediated diseases and pharmaceutical compositions for use in such therapy.
BACKGROUND OF THE INVENTION
Intracellular signal transduction is the means by which cells respond to extracellular stimuli. Regardless of the nature of the cell surface receptor (e. g. protein tyrosine kinase or seven-transmembrane G-protein coupled), protein kinases and phosphatases along with phopholipases are the essential machinery by which the signal is further transmitted within the cell [Marshall, J. C.
Cell,
80, 179-278 (1995)]. Protein kinases can be categorized into five classes with the two major classes being, tyrosine kinases and serine/threonine kinases depending upon whether the enzyme phosphorylates its substrate(s) on specific tyrosine(s) or serine/threonine(s) residues [Hunter, T.,
Methods in Enzymology
(
Protein Kinase Classification
) p. 3, Hunter, T.; Sefton, B. M.; eds. vol. 200, Academic Press; San Diego, 1991].
For most biological responses, multiple intracellular kinases are involved and an individual kinase can be involved in more than one signaling event. These kinases are often cytosolic and can translocate to the nucleus or the ribosomes where they can affect transcriptional and translational events, respectively. The involvement of kinases in transcriptional control is presently much better understood than their effect on translation as illustrated by the studies on growth factor induced signal transduction involving MAP/ERK kinase [Marshall, C. J. Cell, 80, 179 (1995); Herskowitz, I.
Cell.
80, 187 (1995); Hunter, T.
Cell,
80, 225 (1995); Seger, R., and Krebs, E. G.
FASEB J.,
726-735 (1995)].
While many signaling pathways are part of cell homeostasis, numerous cytokines (e.g., IL-1 and TNF) and certain other mediators of inflammation (e.g., COX-2, and iNOS) are produced only as a response to stress signals such as bacterial lippopolysaccharide (LPS). The first indications suggesting that the signal transduction pathway leading to LPS-induced cytokine biosynthesis involved protein kinases came from studies of Weinstein [Weinstein, et al.,
J. Immunol.
151, 3829(1993)] but the specific protein kinases involved were not identified. Working from a similar perspective, Han [Han, et al.,
Science
265, 808(1994)] identified murine p38 as a kinase which is tyrosine phosphorylated in response to LPS. Definitive proof of the involvement of the p38 kinase in LPS-stimulated signal transduction pathway leading to the initiation of proinflammatory cytokine biosynthesis was provided by the independent discovery of p38 kinase by Lee [Lee; et al.,
Nature,
372, 739(1994)] as the molecular target for a novel class of anti-inflammatory agents. The discovery of p38 (termed by Lee as CSBP 1 and 2) provided a mechanism of action of a class of anti-inflammatory compounds for which SK&F 86002 was the prototypic example. These compounds inhibited IL-1 and TNF synthesis in human monocytes at concentrations in the low mM range [Lee, et al.,
Int. J. Immunopharmac.
10(7), 835(1988)] and exhibited activity in animal models which are refractory to cyclooxygenase inhibitors [Lee; et al.,
Annals N. Y. Acad. Sci.,
696, 149(1993)].
REFERENCES:
patent: 3707475 (1972-12-01), Lombardino
patent: 3772441 (1973-11-01), Lombardino
patent: 3929807 (1975-12-01), Fitzi
patent: 3940486 (1976-02-01), Fitzi
patent: 4058614 (1977-11-01), Baldwin
patent: 4199592 (1980-04-01), Cherkofsky
patent: 4447431 (1984-05-01), Sallmann
patent: 4503065 (1985-03-01), Wilkerson
patent: 4566875 (1986-01-01), Cavender
patent: 4686231 (1987-08-01), Bender et al.
patent: 4822805 (1989-04-01), Tasasugi et al.
patent: 5593991 (1997-01-01), Adams et al.
patent: 5593992 (1997-01-01), Adams et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 5658903 (1997-08-01), Adams et al.
patent: 5663334 (1997-09-01), Adams et al.
patent: 5670527 (1997-09-01), Adams et al.
patent: 5686455 (1997-11-01), Adams et al.
patent: 5739143 (1998-04-01), Adams et al.
patent: WO92/10190 (1992-04-01), None
patent: WO92/10498 (1992-06-01), None
patent: WO95/02591 (1995-01-01), None
patent: WO96/21654 (1996-07-01), None
patent: WO96/21452 (1996-07-01), None
patent: WO96/40143 (1996-12-01), None
patent: WO97/25045 (1997-07-01), None
patent: WO97/25046 (1997-07-01), None
patent: WO97/25047 (1997-07-01), None
patent: WO97/25048 (1997-07-01), None
patent: WO 97/36587 (1997-10-01), None
patent: WO 97/12876 (1997-10-01), None
patent: WO97/35855 (1997-10-01), None
patent: WO97/35856 (1997-10-01), None
patent: WO 97/47618 (1997-12-01), None
patent: WO98/22109 (1998-05-01), None
patent: WO 98/47892 (1998-07-01), None
Dinarello et al., Rev.Infect.Disease, 6, p. 51 (1984).
Dinarello, J.Clin.Immun., 5(5), pp. 287-297 (1985).
R.P.Soni, Aust.J.Chem., 35, pp. 1493-1496 (1982).
Poli et al., Proc.Nat'l Acad.Sci., 87, pp.782-784 (1990).
VanLeusen et al., J.O.C., 42, p. 1153 (1977).
Kumada et al., Tetrahedron Letters, 22, p. 5319 (1981).
Pridgen, J.Org.Chem., 47, p. 4319 (1982).
Stille, J Amer Chem.Soc., 109, p. 5478 (1978).
Fischer et al., Rec.Trav.Chim.Pays.Das., 84, p. 439 (1965).
Snieckus, V., Tetrahedron Letters, 29, 2135 (1988).
Terashimia, M., Chem.Pharm.Bull., 11, p. 4755 (1985).
Thompson, W.J., et al., J.Org.Chem., 49, p. 5237 (1984).
Garigipati, R., Tetrahedron Letters, 31, p. 190 (1989).
Engel & Steglich, Liebigs Ann. Chem., 1916 (1978).
Strzybny et al., J.Org.Chem., 28, p. 3381 (1963).
Zavyalov, et al., Khim Farm Zh, 26(3), p. 88 (1992) (With Translation).
Colotta et al., J. Immunol., 132(2), p. 936 (1984).
Simon et al., J. Immunol. Methods, 84, p. 85 (1985).
Becker et al., J Immunol., 147, p. 4307 (1991).
Gilbert, Synthesis, pp. 30-32 (1972).
Morton et al., Tetrahedron Letters, 4123 (1982).
Armarego, W. J. Chem. Soc., (JCSOA9) p. 561 (1962).
Kawasaki et al., J Bio Chem., 272(30), pp. 18518-18521.
Uno, Bull. Chem. Soc. Japan., vol. 69, pp. 1763-1767 (1996).
Katritzky, Synthesis, pp. 45-47 (1993).
Johnson, P.A., J.Chem.Soc., Perkin Trans., vol. 1, pp. 895-905 (1996).
Ishibashi, Chem. Pharm. Bull., 37(8), pp. 2214-2216 (1989).
Adams Jerry Leroy
Boehm Jeffrey Charles
Garigipati Ravi Shanker
Sorenson Margaret
Dinner Dara L.
Kinzig Charles M.
Ramsuer Robert W.
SmithKline Beecham Corporation
Venetianer Stephen
LandOfFree
Cycloalkyl substituted imidazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cycloalkyl substituted imidazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkyl substituted imidazoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2520033